VRDN · Categories · Form 4

VRDN - SEC Form 4 insider transactions

Viridian Therapeutics Inc. (VRDN) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for VRDN

• 59d
  Amendment: Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,031 shares, decreasing direct ownership by 21% to 7,850 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 59d
  Amendment: Chief Operating Officer Beetham Thomas W. covered exercise/tax liability with 3,048 shares, decreasing direct ownership by 19% to 13,361 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 59d
  Amendment: Chief Legal Officer Tousignant Jennifer covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 32% to 3,494 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 59d
  Amendment: President and CEO Mahoney Stephen F. covered exercise/tax liability with 7,408 shares, decreasing direct ownership by 18% to 33,349 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Chief Legal Officer Tousignant Jennifer converted options into 5,169 shares and covered exercise/tax liability with 1,724 shares (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,091 shares and converted options into 6,267 shares, increasing direct ownership by 116% to 7,790 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Amendment: SEC Form 4 filed by Chief Financial Officer Harmon Seth

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Amendment: SEC Form 4 filed by Chief Legal Officer Tousignant Jennifer

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Chief Operating Officer Beetham Thomas W. converted options into 9,409 shares and covered exercise/tax liability with 3,138 shares, increasing direct ownership by 90% to 13,271 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  President and CEO Mahoney Stephen F. converted options into 18,357 shares and covered exercise/tax liability with 7,627 shares, increasing direct ownership by 48% to 33,130 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 125d
  Chief Legal Officer Tousignant Jennifer sold $70,796 worth of shares (2,272 units at $31.16), closing all direct ownership in the company (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Cain Christopher W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Kiselak Tomas

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Morris Arlene

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Ajer Jeffrey Robert

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Gheuens Sarah

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Moses Jennifer K.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 330d
  Director Fairmount Funds Management Llc exercised 14,100 shares at a strike of $11.80 (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 393d
  SEC Form 4 filed by Director Ajer Jeffrey Robert

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 421d
  SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 421d
  SEC Form 4 filed by Director Cain Christopher W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by Chief Legal Officer Tousignant Jennifer

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by President and CEO Mahoney Stephen F.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by Chief Operating Officer Beetham Thomas W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by Chief Financial Officer Harmon Seth

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Gheuens Sarah

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Harwin Peter Evan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Moses Jennifer K.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Morris Arlene

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 766d
  Fairmount Funds Management Llc disposed of 5,859 shares and acquired 5,859 shares (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 813d
  SEC Form 4 filed by Tousignant Jennifer

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 820d
  SEC Form 4 filed by Ciulla Thomas

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 906d
  SEC Form 4 filed by Harmon Seth

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 4 filed by Fairmount Funds Management Llc

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 4 filed by Beetham Thomas W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 4 filed by Mahoney Stephen F.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 955d
  SEC Form 4 filed by Gheuens Sarah

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1052d
  SEC Form 4 filed by Meisner Lara

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Harwin Peter Evan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Kiselak Tomas

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Moses Jennifer K.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Morris Arlene

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1066d
  SEC Form 4 filed by Meisner Lara

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1121d
  SEC Form 4 filed by Myers Scott Dunseth

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1151d
  SEC Form 4: Myers Scott Dunseth bought $160,324 worth of shares (5,500 units at $29.15), increasing direct ownership by 2% to 255,500 units

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1154d
  SEC Form 4: Meisner Lara sold $871,257 worth of shares (29,971 units at $29.07) as part of a pre-agreed trading plan, closing all direct ownership in the company

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1182d
  SEC Form 4 filed by Katz Barrett

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1182d
  SEC Form 4 filed by Melvin Carrie

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1182d
  SEC Form 4 filed by Humer Kristian

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1182d
  SEC Form 4 filed by Meisner Lara

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1185d
  SEC Form 4: Myers Scott Dunseth was granted 250,000 shares

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1185d
  SEC Form 4: Violin Jonathan exercised 50,000 shares at a strike of $0.15 and sold $1,840,000 worth of shares (50,000 units at $36.80) as part of a pre-agreed trading plan (Amendment)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1189d
  SEC Form 4: Violin Jonathan sold $1,840,000 worth of shares (50,000 units at $36.80) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 430,905 units

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1198d
  SEC Form 4: Meisner Lara exercised 6,843 shares at a strike of $20.56 and sold $244,021 worth of shares (6,843 units at $35.66) as part of a pre-agreed trading plan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1205d
  SEC Form 4: Katz Barrett exercised 29,000 shares at a strike of $23.03 and sold $1,078,261 worth of shares (29,000 units at $37.18) as part of a pre-agreed trading plan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1212d
  SEC Form 4: Katz Barrett sold $2,089,472 worth of shares (60,000 units at $34.82) as part of a pre-agreed trading plan and exercised 60,000 shares at a strike of $23.03

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1232d
  SEC Form 4: Meisner Lara exercised 16,926 shares at a strike of $23.03 and sold $493,398 worth of shares (16,926 units at $29.15) as part of a pre-agreed trading plan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1235d
  SEC Form 4: Meisner Lara exercised 1,597 shares at a strike of $23.03 and sold $45,311 worth of shares (1,597 units at $28.37) as part of a pre-agreed trading plan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1240d
  SEC Form 4: Meisner Lara exercised 16,256 shares at a strike of $23.03 and sold $457,077 worth of shares (16,256 units at $28.12) as part of a pre-agreed trading plan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

Other VRDN categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends